TriangleSirolimus (NCT07581704)
Sirolimus trial for Multiple Myeloma (NCT07581704). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for relapsed or refractory multiple myeloma in adults who were previously exposed to T cell engager therapy.
The idea: prepare the immune system first. Patients receive short pre conditioning with sirolimus before a T cell engaging bispecific antibody, teclistamab or talquetamab. The study tests safety, and whether pre conditioning changes the ratio of effector to exhausted T cells.
This is a single center phase 1b study of 10 patients. At the University of Iowa in Iowa City, Christopher Strouse leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.